Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months~* Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use \[≤14 consecutive days\] for acute conditions)~* HbA1c ≥7.5% to ≤11.0% at screening~* Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment~* Body mass Index (BMI) ≥23 kilograms per meter squared~Exclusion Criteria:~* Type 1 diabetes mellitus~* Have history of chronic or acute pancreatitis~* Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment~* Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months~* Have a history of ketoacidosis or hyperosmolar state/coma~* Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility~* Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months~* Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
- 10 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 10 mg tirzepatide administered SC QW.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 15 mg tirzepatide administered SC QW.
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).